Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Jefferam1on Jan 11, 2017 1:27pm
117 Views
Post# 25694864

RE:RE:RE:Where is this headedÉ

RE:RE:RE:Where is this headedÉOne can only dream.
I wish I could remember all the history on this past example. Perhaps someone can pull up an old chart but I'm not sure where to find one.
I while back somewhere in 2005-2010, I can't remember the dates. I was invested in a drug company called Liponex. It was making a drug to reduce the bad cholesterol. If I recall it when through multiple clinical trials and was bouncing around from cents (0.40-0.60? ) to dollars (~3.00) all while in clinical trial.
The last trial they did, it showed that the drug actually increased the bad cholesterol rather than lower it. Needless to say, that's why I can't find any charts anymore.
But my point was it was able to bounce from pennies to multiple dollars all during clinical trial phases.
No reason Antibe can't do the same.
Then if successful and they go to production, one can only dream.
Bullboard Posts